$ENDP
RBC Capital " After the close, ENDP reported 2Q revenue and adjusted EBITDA of $714 million and $343 million, coming in well ahead of Street at $663 million and $291 million (see variance below). The beat reflects broad strength across all four of the company's segments, including key products XIAFLEX and Vasostrict. ENDP raised the low end of its full-year 2021 guidance for revenue, adjusted EBITDA, and adjusted EPS, and also modestly increased its product specific revenue guidance for XIAFLEX and Vasostrict."